key: cord-0731399-ymmrfcwq
authors: Al‐Hail, Hamad; Mirza, Faheem; Al Hashemi, Alaa; Ahmad, Muneera Naseer; Iqbal, Muhammad; Tang, Patrick; Hasan, Mohammad Rubayet
title: Evaluation of automated molecular tests for the detection of SARS‐CoV‐2 in pooled nasopharyngeal and saliva specimens
date: 2021-06-16
journal: J Clin Lab Anal
DOI: 10.1002/jcla.23876
sha: 6754c544d2e4fa3f98e9d268db0ee744a7453f25
doc_id: 731399
cord_uid: ymmrfcwq

BACKGROUND: Pooling of samples for SARS‐CoV‐2 testing in low‐prevalence settings has been used as an effective strategy to expand testing capacity and mitigate challenges with the shortage of supplies. We evaluated two automated molecular test systems for the detection of SARS‐CoV‐2 RNA in pooled specimens. METHODS: Pooled nasopharyngeal and saliva specimens were tested by Qiagen QIAstat‐Dx Respiratory SARS‐CoV‐2 Panel (QIAstat) or Cepheid Xpert Xpress SARS‐CoV‐2 (Xpert), and the results were compared to that of standard RT‐qPCR tests without pooling. RESULTS: In nasopharyngeal specimens, the sensitivity/specificity of the pool testing approach, with 5 and 10 specimens per pool, were 77%/100% (n = 105) and 74.1%/100% (n = 260) by QIAstat, and 97.1%/100% (n = 250) and 100%/99.5% (n = 200) by Xpert, respectively. Pool testing of saliva (10 specimens per pool; n = 150) by Xpert resulted in 87.5% sensitivity and 99.3% specificity compared to individual tests. Pool size of 5 or 10 specimens did not significantly affect the difference of RT‐qPCR cycle threshold (C(T)) from standard testing. RT‐qPCR C(T) values obtained with pool testing by both QIAstat and Xpert were positively correlated with that of individual testing (Pearson's correlation coefficient r = 0.85 to 0.99, p < 0.05). However, the C(T) values from Xpert were significantly stronger (p < 0.01, paired t test) than that of QIAstat in a subset of SARS‐CoV‐2 positive specimens, with mean differences of −4.3 ± 2.43 and −4.6 ± 2 for individual and pooled tests, respectively. CONCLUSION: Our results suggest that Xpert SARS‐CoV‐2 can be utilized for pooled sample testing for COVID‐19 screening in low‐prevalence settings providing significant cost savings and improving throughput without affecting test quality.

Rapid testing to detect individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is central to the management of the ongoing pandemic of coronavirus disease 2019 . 1 Since the beginning of the outbreak, detection of viral RNA in nasopharyngeal (NP) swab specimens by real-time reverse transcription PCR (RT-qPCR) remains the main approach for identifying patients with acute infections. 2 The choice of a method for SARS-CoV-2 RT-qPCR depends on multiple factors including required test throughput, rate of positivity, and the availability of resources. Predesigned assays recommended by the World Health Organization (WHO), targeting several SARS-CoV-2 genes, were made public to enable the development of relatively inexpensive, laboratory-developed RT-qPCR tests early in the outbreak. Many commercial assays have also been developed in singleplex or multiplex formats to test for SARS-CoV-2 RNA. These tests are designed for high-complexity laboratories that perform large volume testing.

However, these tests may be difficult to implement in laboratories with limited expertise in molecular testing. To this end, molecular testing devices that integrate RNA extraction and RT-qPCR with random-access features with sample-to-result capability are ideally suited for laboratories that may not be able to deal with highcomplexity molecular testing. These test methods and platforms are also suitable for testing in a near point-of-care (POC) setting. 3 

Cepheid Xpert Xpress SARS-CoV-2 (Xpert) tests are among the few fully automated, near POC solutions for COVID-19 testing that are FDA approved under emergency use authorization (EUA). While Xpert detects multiple targets within the SARS-CoV-2 genome, QIAstat is a multiplexed RT-qPCR test for the detection of multiple respiratory pathogens, including the SARS-CoV-2 virus in nasopharyngeal specimens. [4] [5] [6] Although these tests are rapid and convenient, they are more expensive than laboratory-developed assays and have lower throughput as each instrument module can only test one sample at a time. The throughput of tests can be improved by using multiple systems or by increasing the number of modules. The GeneXpert systems are available in 1-16 module configurations, and the larger GeneXpert Infinity systems offer a maximum throughput of >2,300 tests per day. However, GeneXpert modules are expensive and significant capital investment is necessary to achieve such test capacity. Pooling of multiple specimens, in low-prevalence settings, may significantly reduce the cost of the commercial, automated molecular tests and improve the throughput of these assays. Pooling of specimens to reduce cost and expand the capacity of COVID-19 testing has been well described in the literature. [9] [10] [11] [12] [13] [14] Pooled sample testing was also encouraged by FDA for the screening of asymptomatic individuals for COVID-19. 15 While the pooled sample testing approach was evaluated using laboratory-developed, standard RT-qPCR tests, data on pool testing with automated molecular tests systems such as QIAstat and Xpert are limited. 16, 17 In this study, we evaluated and compared pool testing approach using QIAstat and Xpert on both nasopharyngeal and saliva specimens. Pool test results were verified by individual tests by a WHOrecommended, standard RT-qPCR assay. For a subset of specimens, pool results were also compared to individual test results by the respective commercial tests. NucliSENS EasyMAG (bioMerieux) followed by RT-qPCR, based on one of the assays recommended by the WHO. 18 The performance standards of the standard method were established in our laboratory according to College of American Pathologists (CAP) guidelines. By using quantitative synthetic SARS-CoV-2 RNA control (Twist Bioscience, CA), the limit of detection of the assay was estimated to be <10 copies/reaction. By testing external quality assessment (EQA) specimens (CAP and Quality Control for Molecular Diagnostics, QCMD), and specimens previously tested in a reference laboratory, the accuracy of the assay is >95%. Both QIAstat and Xpert are fully automated, multiplex real-time RT-PCR tests. While

QIAstat is intended to detect multiple respiratory pathogens, including SARS-CoV-2, Xpert is designed to detect the E and N genes of SARS-CoV-2. A total of 815 NPFS and 150 saliva specimens were simultaneously assessed by the standard approach and one of the pool testing approaches in this study. For pool testing, 0.1 ml of each of the 5 or 10 specimens was pooled together, vortexed for 10 s, 

Nasopharyngeal flocked swab specimens were tested by QIAstat either in a pool of 5 specimens (pool-5) or in a pool of 10 specimens (pool-10) ( Table 1 ). For pool-5 testing, a total of 10 pooled runs (n = 50 specimens) that gave positive results and 11 pooled runs (n = 55 specimens) that gave negative results by QIAstat were individually assessed by standard RT-qPCR. For pool-10 testing, specimens in 14 positive pools (n = 140 specimens) and 12 negative pools (n = 120 specimens) by QIAstat were individually assessed. QIAstat test results for respiratory pathogens other than SARS-CoV-2 were disregarded. By individual testing, a total of 6 pools had >1 positive samples in the pool-10 group (Table S1) . Among these pools, two were undetectable by QIAstat pool-10 testing. In both pool groups, all of the positive pool results were correct, but 3 of 10 negative pool-5 results and 5 of 12 negative pools in pool-10 results were falsely negative after individual assessment. The sensitivity, specificity, and accuracy of QIAstat pool-5 and pool-10 against standard individual testing were not significantly different (Table 1) . A total of 10 positive results were missed by the QIAstat pool testing approach: The RT-qPCR C T values by the standard method for these specimens ranged from 32.6 to 38.3. To investigate whether lower analytical sensitivity of QIAstat was responsible for these discrepant results, we individually tested some of these specimens by QIAstat and noted that the positive samples, that were missed by pooled testing, were also negative by individual QIAstat testing, although they were positive by two other methods (Table S2) 

For the positive pools that gave multiple positive results by individual assessment, the lowest (strongest) C T was used for analysis (Table S1 ).

(F) mean C T value difference (ΔC T ) between pool C T and standard individual C T with 95% confidence intervals (CI). Statistical significance (p) of difference of ΔC T between different groups was calculated by Mann-Whitney U test (Table S1 ). All pool test results, except one, were correct in each of the pool-5 and pool-10 groups. The sensitivity, specificity, and accuracy of Xpert pool testing in NP specimens against standard, individual testing were >95% in both group and were not affected by pool size of 5 or 10 specimens ( Table 1) Figure 1F ). However, the mean C T value difference of QIAstat vs Xpert pool testing (ΔC T ) from standard testing was significantly different (p < 0.01) ( Figure 1F ).

For testing of pooled saliva specimens by Xpert, a total of 8 pooled runs (n = 80 specimens) that gave positive results and 7 pooled runs (n = 70 specimens) that gave negative results were individually assessed by standard RT-qPCR. All except two (87%) pooled test results were correct. The sensitivity, specificity, and accuracy of saliva pool testing by Xpert against standard, individual testing were 87.5%, 99.3%, and 98.7%, respectively (Table 1) . For samples that were positive by both methods, the RT-qPCR C T values were positively correlated (Pearson's correlation coefficient r = 0.8535, p < 0.05) ( Figure 1E ). Mean C T value change (ΔC T ) because of pooling 10 saliva specimens was not significantly different from pool-10 testing of NP swab specimens (p = 0.6507) ( Figure 1F ). In order to improve the throughput of these assay, large number of modules are necessary which requires a larger capital investment.

As an alternative solution, we performed pooled specimen testing using these platforms and compared the accuracy of results with that of standard RT-qPCR. Our new pooled test approach demonstrated equivalent results to standard testing, in particular with

Xpert test and significantly saved costs. The lower sensitivity of pooled sample run using QIAstat is related to the lower analytical sensitivity of the assay compared to other methods ( Figure 2 , Table   S1 ) rather than because of sample pooling. For both test platforms, a pool size of 5 or 10 specimens did not significantly affect the sensitivity of the pooled testing approach (Table 1, Figure 1F ). 

We are grateful for the efforts of all technologists in the Molecular

Infectious Disease Laboratory at Sidra Medicine.

All data generated or analyzed during this study are included in this published article (and its Supplementary Information files) .

Mohammad Rubayet Hasan https://orcid. org/0000-0002-4658-7949

The epidemiology, diagnosis and treatment of COVID-19

Information for Laboratories about Coronavirus (COVID-19) 2020

Laboratory diagnosis of COVID-19: current issues and challenges

Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the first rapid multiplex PCR commercial assay for SARS-CoV-2 detection

Clinical evaluation of three sample-to-answer platforms for detection of SARS-CoV-2

Multicenter evaluation of the cepheid Xpert Xpress SARS-CoV-2 test

ASM. Supply shortages impacting COVID-19 and non-COVID testing

Labor atory -Suppl y-Short ages-Are-Impac ting-COVID -19?utm_sourc e=RealM agnet &utm_mediu m=email &utm_conte nt= COVID %2D19%5FNew s%5F202 01021 &utm_ campa ign=Sci%20Top ics%20%3E%20COV ID%2D19

A novel strategy for community screening of SARS-CoV-2 (COVID-19): sample pooling method

Pooled saliva samples for COVID-19 surveillance programme

Pooling of samples for testing for SARS-CoV-2 in asymptomatic people

Evaluation of COVID-19 RT-qPCR test in multi-sample pools

Pooling of nasopharyngeal (NP) swab samples to overcome global shortage of rRT-PCR COVID-19 test kits

Effectiveness of sample pooling strategies for SARS-CoV-2 mass screening by RT-PCR: a scoping review

Pooled Sample Testing and Screening Testing for COVID-19 2020

Sample pooling on the Cepheid Xpert(R) Xpress SARS-CoV-2 assay

Asymptomatic patient testing after 10:1 pooling using the Xpert Xpress SARS-CoV-2 assay

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

WHO. Pooling samples boosts Ghana's COVID-19 testing 2020

Guidance for Use of Pooling Procedures in SARS-CoV-2 Diagnostic, Screening, and Surveillance Testing 2020